Cyclerion Therapeutics, Inc. (CYCN)
Develops experimental drugs targeting rare heart and kidney diseases.
$3.50+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+34.9%
The outlook
CYCN is trading near the lower end of its 52-week range, sitting above both its 50- and 200-day moving averages. Analyst coverage is bullish, with an average price target implying roughly 129% upside from current levels. The stock's position in its recent trend and analyst sentiment currently lean constructive.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +129% vs current price
Market cap
$15.2M
52-wk high
$8.48
52-wk low
$1.03
50-day avg
$3.32
200-day avg
$2.28
Trailing P/E
—